Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Current Portion of Long-Term Debt
kr94m
CAGR 3-Years
17%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Current Portion of Long-Term Debt
kr15.9m
CAGR 3-Years
1%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Current Portion of Long-Term Debt
€21.4m
CAGR 3-Years
45%
CAGR 5-Years
35%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Current Portion of Long-Term Debt
kr41.9m
CAGR 3-Years
-68%
CAGR 5-Years
21%
CAGR 10-Years
17%
F
Fluoguide AS
STO:FLUO
Current Portion of Long-Term Debt
kr10.2m
CAGR 3-Years
299%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Current Portion of Long-Term Debt
kr2.2m
CAGR 3-Years
8%
CAGR 5-Years
-5%
CAGR 10-Years
60%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
94m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Current Portion of Long-Term Debt amounts to 94m DKK.

What is Genmab A/S's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
25%

Over the last year, the Current Portion of Long-Term Debt growth was 15%. The average annual Current Portion of Long-Term Debt growth rates for Genmab A/S have been 17% over the past three years , 25% over the past five years .

Back to Top